Donald L. Siegel

faculty photo
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Dept. Pathology & Lab Med, Penn-Presbyterian Medical Center
Director, ACGME-accredited Fellowship Program in Blood Banking/Transfusion Medicine, Hospital of the University of PA
Medical Director, AABB-accredited Blood Bank and Apheresis Unit, Hospital of the University of Pennsylvania
Member for Oversight of Blood Usage, Clinical Effectiveness and Quality Improvement Committee, Hospital of the University of PA
Medical Director, FACT-accredited cell collection and processing facilities for Hematopoietic Stem Cell Transplant Program, Hospital of the University of Pennsylvania
Member, Executive Committee, Dept of Pathology & Lab Med, University of Pennsylvania School of Medicine
Attending Physician, Division of Transfusion Med, Dept. Pathology & Lab Med, Hospital of the University of PA
Founding Director, Division of Transfusion Medicine & Therapeutic Pathology, Hospital of the University of PA
Member, Cell & Vaccine Production Facility Advisory Committee, University of Pennsylvania School of Medicine
Director, Clinical Cell and Vaccine Production Facility, Center for Advanced Cellular Therapeutics, University of Pennsylvania School of Medicine
Department: Pathology and Laboratory Medicine

Contact information
9-112 South Tower, Big 421
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: (215) 662-3942
Lab: (215) 898-9655
Education:
Sc.B. (Biophysics)
Brown University, 1977.
Ph.D. (Biophysics)
Harvard University, 1983.
M.D.
University of Pennsylvania, 1987.
Permanent link
 

Description of Research Expertise

Research Interests

Discovery and characterization of diagnostic and therapeutic monoclonal antibodies

Research Summary

My laboratory studies human immune repertoires in health and disease using phage display technologies for the production of human and non-human monoclonal antibodies relevant to transfusion medicine, benign hematology, infectious diseases, and oncology. Current studies focus on developing targeted drug delivery methods using red cell antibodies coupled to novel anti-thrombotic/anti-inflammatory molecules; cloning monoclonal primate neutralizing Dengue, Ebola, MERS and Zika virus antibodies for human in vivo antibody gene expression therapy; and isolating recombinant human and humanized antibody fragments for the design of T-cell chimeric antigen receptors for cancer therapy.

Selected Publications

Villa, C.H., Pan, D.C., Johnston, I., Greineder, C.F., Walsh, L., Hood, E., Cines, D.B., Poncz, M., Siegel, D.L., Muzykantov, V.R.: Biocompatible coupling of therapeutic fusion proteins to human erythrocytes. Blood Advances 2: 165-176, 2018.

Villa, C.H., Marcos-Contreras, O.A., Greineder, C.F., Hood, E., Shuvaeva, T., Walsh, L., Meyerson, J., Glassman, P., Brenner, J.S., Siegel, D.L., Muzykantov, V.R. : Red blood cell targeting of liposomes provides markedly enhanced circulation. Center for Targeted Therapeutics and Translation Nanomedicine Annual Symposium 2017.

Villa C.H., Cines D.B., Siegel D.L., Muzykantov V.R.: Erythrocytes as carriers for drug delivery in blood transfusion and beyond. Transfusion Medicine Reviews 31: 26-35, 2017.

Fraietta J.A., Lacey S.F., Orlando E.J., Pruteanu-Malinici I., Gohil M., Lundh S., Boesteanu A.C., Wang Y., O’Connor R.S., Hwang W.-T., Pequignot E., Ambrose D.E., Zhang C., Wilcox N., Bedoya F., Dorfmeir C., Chen F., Tian L., Parakandi H., Gupta M., Young R.M., Johnson F.B., Kulikovskaya I., Liu L., Xu J., Kassim S.H., Suhoski-Davis M.M., Levine B.L., Frey N.V., Siegel D.L., Huang A.C., Wherry E.J., Bitter H., Brogdon J.L., Porter D.L., June C.H., Melenhorst J.J.: Identification of functional determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Blood 130: 3181, 2017.

Carnemolla, R., Villa, C.H., Greineder, C.F., Zaitsev, S., Kowalska, A., Atochin, D.N., Cines, D.B., Siegel, D.L., Esmon, C.T. Muzykantov, V.R.: Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury. FASEB J 31: 761-770, 2017.

Beigel, J.H., Tebas, P., Elie-Turenne, Marie-Carmelle, et al: Immune plasma for the treatment of severe influenza: an open-label, multicenter, phase 2 randomised study. The Lancet Respiratory Medicine 5: 500-511, 2017.

Chen, J., Zheng, Q., Hammers, C.M., Ellebrecht, C., Mukherjee, C., Tang, H-Y., Lin, C., Yuan, H-J., Pan, M., Langenhan, J., Komorowski, L., Siegel, D.L., Payne, A.S., Stanley, J.R.: Proteomic analysis of pemphigus autoantibodies indicates a much larger, more diverse, and dynamic repertoire than determined by B-cell genetics. Cell Reports 18: 237-247, 2017.

Ostertag, E.M., Bdeir, K., Kacir, S., Thiboutot, M., Gulendran, G., Yunk, L., Hayes, V.M., Motto, D.G., Poncz, M., Zheng, X.L., Cines, D.B., Siegel, D.L.: ADAMTS13 Autoantibodies Cloned from Patients with Acquired Thrombotic Thrombocytopenic Purpura: 2. Pathogenicity in an animal model. Transfusion 56: 1775-1785, 2016.

Zhao A., Tohidkia M.R., Siegel D.L., Coukos G., Omidi Y.: Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy. Critical Reviews in Biotechnology 36: 276-289, 2016.

Ostertag, E.M., Kacir, S., Thiboutot, M., Gulendran, G., Zheng, X.L., Cines, D.B., Siegel, D.L.: ADAMTS13 Autoantibodies Cloned from Patients with Acquired Thrombotic Thrombocytopenic Purpura: 1. Structural and functional characterization in vitro. Transfusion 56: 1763-1774, 2016.

back to top
Last updated: 02/25/2018
The Trustees of the University of Pennsylvania